The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...

The Diabetic Care Devices Market is projected to grow from $16.6 billion in 2024 to $26.8 billion by 2029, at a CAGR of 10.1%. This report provides a comprehensive analysis of diabetes monitoring ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

To make a type 2 diabetes diagnosis, doctors can use several different blood tests. You’ll typically need to be tested at least twice to confirm a diagnosis. Most people are tested for diabetes ...

This guide covers all the logo design rules, best practices, tips, examples, and more to equip you with the knowledge for crafting brilliant logos. Logos are one of the most vital elements of any ...

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, as the Swiss drugmaker seeks to boost its prospects in the booming ...

BERLIN (Reuters) -Roche has entered an exclusive collaboration and licensing agreement with Danish obesity drug maker Zealand Pharma to co-develop petrelintide as an obesity therapy drug, the Swiss ...

Roche shares gained 5.5%. Zealand is testing petrelintide, opens new tab in overweight or obese individuals without type 2 diabetes in a mid-stage study. Petrelintide belongs to a class of drugs ...

When your blood sugar levels fall within the recommended ranges, it’s a sign your diabetes treatment and management plan is working. You and your doctor can determine your exact blood sugar targets.

People with diabetes looking for a sweetener that won't raise their blood sugar levels frequently turn to sugar substitutes. There are several sugar alternatives that are considered safe and may be ...

Roche Holding AG hired a senior executive from rival Novo Nordisk A/S as the Swiss drugmaker prepares to enter the hyper-competitive market for obesity drugs. Morten Lammert will join Roche as its ...